Matinas Biopharma Holdings Inc

ASE:MTNB  
0.79
-0.01 (-1.62%)
Other Pre-Announcement

Matinas BioPharma Reports Q4 Loss Per Share Of $0.03

Published: 03/29/2021 11:29 GMT
Matinas Biopharma Holdings Inc (MTNB) - Matinas Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights.
Q4 Loss per Share $0.03.
Q4 Earnings per Share Estimate $-0.03 -- Refinitiv Ibes Data (analyst estimates).
Matinas Biopharma - Enrollment Continues in Second Patient Cohort of Enact Study of Mat2203 in Cryptococcal Meningitis.
Matinas Biopharma - Dsmb Review and Cohort Progression in Enact Study of Mat2203 in Cryptococcal Meningitis is Anticipated in Q3 of 2021.
Cash on Hand is Sufficient to Fund Operations Into 2024.